This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delwart, E. L.
Right arrow Articles by Markowitz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delwart, E. L.
Right arrow Articles by Markowitz, M.

 Previous Article  |  Next Article 

J Virol, March 1998, p. 2416-2421, Vol. 72, No. 3
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Rapid, Transient Changes at the env Locus of Plasma Human Immunodeficiency Virus Type 1 Populations during the Emergence of Protease Inhibitor Resistance

Eric L. Delwart,1,* Heng Pan,1 Avidan Neumann,2 and Martin Markowitz1

Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016,1 and Department of Life Sciences, Bar-Ilan University, Ramat-Gan 52900, Israel2

Received 4 September 1997/Accepted 19 November 1997

Plasma human immunodeficiency virus type 1 (HIV-1) populations were genetically analyzed at their most variable locus, the envelope gene, during the rapid emergence of resistance to protease inhibitor monotherapy. Plasma virus populations remained genetically constant prior to drug treatment and during the 1 to 2 weeks following initiation of therapy, while viremia fell 10- to 100-fold. Concomitant with rapid plasma viremia rebounds associated with the emergence of drug-resistant virus, marked alterations were then detected at the env locus. Plasma population changes lasted only a few weeks before the reappearance of the pretreatment envelope variants. The emergence of resistance to single protease inhibitors was therefore associated with major but transient changes at a nonselected locus. Selection for resistance to single protease inhibitors thus appears to be more complex than the continued replication of a large, random, and therefore genetically representative sampling of the pretreatment plasma population. The possibility that drug-privileged anatomical sites containing distinct envelope variants and/or a small effective HIV-1 population size account for these results is discussed.

* Corresponding author. Mailing address: Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave., New York, NY 10016. Phone: (212) 725-0018. Fax: (212) 725-1126. E-mail: delwart{at}adarc.org.




This article has been cited by other articles:

  • Ambrose, Z., Palmer, S., Boltz, V. F., Kearney, M., Larsen, K., Polacino, P., Flanary, L., Oswald, K., Piatak, M. Jr., Smedley, J., Shao, W., Bischofberger, N., Maldarelli, F., Kimata, J. T., Mellors, J. W., Hu, S.-L., Coffin, J. M., Lifson, J. D., KewalRamani, V. N. (2007). Suppression of Viremia and Evolution of Human Immunodeficiency Virus Type 1 Drug Resistance in a Macaque Model for Antiretroviral Therapy. J. Virol. 81: 12145-12155 [Abstract] [Full Text]  
  • Nora, T., Charpentier, C., Tenaillon, O., Hoede, C., Clavel, F., Hance, A. J. (2007). Contribution of Recombination to the Evolution of Human Immunodeficiency Viruses Expressing Resistance to Antiretroviral Treatment. J. Virol. 81: 7620-7628 [Abstract] [Full Text]  
  • Ray, N., Harrison, J. E., Blackburn, L. A., Martin, J. N., Deeks, S. G., Doms, R. W. (2007). Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility of Human Immunodeficiency Virus Type 1 to Other Classes of Entry Inhibitors. J. Virol. 81: 3240-3250 [Abstract] [Full Text]  
  • Fernandez, G., Clotet, B., Martinez, M. A. (2007). Fitness Landscape of Human Immunodeficiency Virus Type 1 Protease Quasispecies. J. Virol. 81: 2485-2496 [Abstract] [Full Text]  
  • Charpentier, C., Nora, T., Tenaillon, O., Clavel, F., Hance, A. J. (2006). Extensive Recombination among Human Immunodeficiency Virus Type 1 Quasispecies Makes an Important Contribution to Viral Diversity in Individual Patients. J. Virol. 80: 2472-2482 [Abstract] [Full Text]  
  • Kitrinos, K. M., Nelson, J. A. E., Resch, W., Swanstrom, R. (2005). Effect of a Protease Inhibitor-Induced Genetic Bottleneck on Human Immunodeficiency Virus Type 1 env Gene Populations. J. Virol. 79: 10627-10637 [Abstract] [Full Text]  
  • Kapoor, A., Jones, M., Shafer, R. W., Rhee, S.-Y., Kazanjian, P., Delwart, E. L. (2004). Sequencing-Based Detection of Low-Frequency Human Immunodeficiency Virus Type 1 Drug-Resistant Mutants by an RNA/DNA Heteroduplex Generator-Tracking Assay. J. Virol. 78: 7112-7123 [Abstract] [Full Text]  
  • Magierowska, M., Bernardin, F., Garg, S., Staprans, S., Miller, M. D., Van Rompay, K. K. A., Delwart, E. L. (2004). Highly Uneven Distribution of Tenofovir-Selected Simian Immunodeficiency Virus in Different Anatomical Sites of Rhesus Macaques. J. Virol. 78: 2434-2444 [Abstract] [Full Text]  
  • Dybul, M., Daucher, M., Jensen, M. A., Hallahan, C. W., Chun, T.-W., Belson, M., Hidalgo, B., Nickle, D. C., Yoder, C., Metcalf, J. A., Davey, R. T., Ehler, L., Kress-Rock, D., Nies-Kraske, E., Liu, S., Mullins, J. I., Fauci, A. S. (2003). Genetic Characterization of Rebounding Human Immunodeficiency Virus Type 1 in Plasma during Multiple Interruptions of Highly Active Antiretroviral Therapy. J. Virol. 77: 3229-3237 [Abstract] [Full Text]  
  • Doukhan, L., Delwart, E. (2001). Population Genetic Analysis of the Protease Locus of Human Immunodeficiency Virus Type 1 Quasispecies Undergoing Drug Selection, Using a Denaturing Gradient-Heteroduplex Tracking Assay. J. Virol. 75: 6729-6736 [Abstract] [Full Text]  
  • Ikuta, K., Suzuki, S., Horikoshi, H., Mukai, T., Luftig, R. B. (2000). Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis. Microbiol. Mol. Biol. Rev. 64: 725-745 [Abstract] [Full Text]  
  • Nelson, J. A. E., Baribaud, F., Edwards, T., Swanstrom, R. (2000). Patterns of Changes in Human Immunodeficiency Virus Type 1 V3 Sequence Populations Late in Infection. J. Virol. 74: 8494-8501 [Abstract] [Full Text]  
  • Ibáñez, A., Clotet, B., Martínez, M.-A. (2000). Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. J. Gen. Virol. 81: 85-95 [Abstract] [Full Text]  
  • Kashuba, A. D. M., Dyer, J. R., Kramer, L. M., Raasch, R. H., Eron, J. J., Cohen, M. S. (1999). Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 43: 1817-1826 [Full Text]  
  • Pawlotsky, J.-M., Germanidis, G., Frainais, P.-O., Bouvier, M., Soulier, A., Pellerin, M., Dhumeaux, D. (1999). Evolution of the Hepatitis C Virus Second Envelope Protein Hypervariable Region in Chronically Infected Patients Receiving Alpha Interferon Therapy. J. Virol. 73: 6490-6499 [Abstract] [Full Text]  
  • Nijhuis, M., Boucher, C. A. B., Schipper, P., Leitner, T., Schuurman, R., Albert, J. (1998). Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc. Natl. Acad. Sci. USA 95: 14441-14446 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»